Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting
Includes presentation of additional late-breaking Phase 3 ATHENA-MONO trial data as complement to previously announced topline data BOULDER, Colo.–(BUSINESS WIRE)– Clovis Oncology, Inc. (NASDAQ: CLVS),...